Ocular Therapeutix (OCUL) CCO receives 136K RSUs and 416K stock options
Rhea-AI Filing Summary
Ocular Therapeutix’s Global Chief Commercial Officer, David Wayne Robinson, reported new equity awards. On January 21, 2026, he received 136,000 restricted stock units (RSUs) of common stock at a price of $0. Each RSU represents one share of common stock and will vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in equal annual installments thereafter, subject to continued service.
On the same date, he was also granted a stock option for 416,000 shares of common stock at an exercise price of $11.42 per share. This option vests over four years: 25% of the underlying shares vest on the one-year anniversary of his first date of employment, and the balance vests in equal monthly installments over the following three years, contingent on continued service. After these grants, he directly holds 136,000 shares of common stock and 416,000 stock options.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 416,000 | $0.00 | -- |
| Grant/Award | Common Stock | 136,000 | $0.00 | -- |
Footnotes (1)
- On January 21, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2019 Inducement Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. This option was granted on January 21, 2026 and vests over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the reporting person's first date of employment and the remainder vesting in equal monthly installments over the three years after such date.
FAQ
What insider transaction did OCUL’s Global CCO report on this Form 4?
The Global Chief Commercial Officer, David Wayne Robinson, reported receiving 136,000 RSUs of common stock and a stock option for 416,000 shares on January 21, 2026, both as equity compensation.
How many restricted stock units were granted to David Wayne Robinson at Ocular Therapeutix (OCUL)?
He was granted 136,000 restricted stock units (RSUs), each representing one share of Ocular Therapeutix common stock, at a price of $0 per unit.
What are the vesting terms for the OCUL RSUs granted to the Global CCO?
The 136,000 RSUs vest over three years: one-third vests on the one-year anniversary of the grant date, and an additional one-third vests at the end of each of the next two one-year periods, subject to continued service.
How does the stock option granted to OCUL’s Global CCO vest over time?
The option vests over four years: 25% of the shares vest on the one-year anniversary of his first date of employment, and the remaining shares vest in equal monthly installments over the following three years, as long as he continues to serve the company.
How many OCUL securities does David Wayne Robinson hold after these grants?
Following the reported transactions, he directly holds 136,000 shares of common stock and 416,000 stock options linked to Ocular Therapeutix common stock.